Amneal launches first biosimilar with alymsys® (bevacizumab-maly) in the united states

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) (“amneal” or the “company”) today announced the commercial launch of alymsys® (bevacizumab-maly), a biosimilar referencing avastin®. alymsys® is a vascular endothelial growth factor inhibitor used in oncology. this product was developed by mabxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. “the launch of alymsys provides ad
AMRX Ratings Summary
AMRX Quant Ranking